Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Acute 5Burkitt Lymphoma 3Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, T-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Hematologic Neoplasms 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 5fludarabine 3Clofarabine 3thymoglobulin 2fludarabine phosphate 2Vorinostat 2Polymerase Chain Reaction 2Methotrexate 2Isotretinoin 2Gemtuzumab 2Flow Cytometry 2Busulfan 2Azacitidine 2Antilymphocyte Serum 2tipifarnib 1ruxolitinib 1merphos 1imetelstat 1hydrocortisone hemisuccinate 1cc-486 1Whole-Body Irradiation 1Topotecan 1Thiotepa 1Tacrolimus 1Spinal Puncture 1Specimen Handling 1Radioimmunotherapy 1N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 1Mycophenolic Acid 1MK 2206 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Juvenile × merphos × Clear all
NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡